Advertisement

Antibody-Drug Conjugates

The 21st Century Magic Bullets for Cancer

  • Jeffrey Wang
  • Wei-Chiang Shen
  • Jennica L. Zaro

Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 17)

Table of contents

  1. Front Matter
    Pages i-x
  2. Introduction

    1. Front Matter
      Pages 1-1
  3. The ADC Construct

    1. Front Matter
      Pages 9-9
    2. Chalet Tan
      Pages 11-22
    3. Michael Ritchie, Laird Bloom, Gregory Carven, Puja Sapra
      Pages 23-48
    4. E. Erica Hong, Ravi Chari
      Pages 49-76
  4. Development Issues

    1. Front Matter
      Pages 77-77
    2. Junyan A. Ji, Jun Liu, Y. John Wang
      Pages 79-95
    3. Karen J. Cha
      Pages 133-149
  5. Landscape, IP and Pharmacoeconomics

  6. Case Studies

    1. Front Matter
      Pages 177-177
    2. Yun Luo, Jérôme J. Lacroix, Sunil Prabhu
      Pages 203-223
  7. From Today to Tomorrow

    1. Front Matter
      Pages 233-233
    2. Jennica L. Zaro, Jeffery Wang, Wei-Chiang Shen
      Pages 235-250
  8. Back Matter
    Pages 251-252

About this book

Introduction

This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.

Keywords

antibody bio-analysis immunotoxin linkers payloads

Editors and affiliations

  • Jeffrey Wang
    • 1
  • Wei-Chiang Shen
    • 2
  • Jennica L. Zaro
    • 3
  1. 1.Western University of Health Sciences, Department of Pharmaceutical SciencesPomonaUSA
  2. 2.University of Southern California, Department of Pharmacology and Pharmaceutical SciencesLos AngelesUSA
  3. 3.University of Southern California, Department of Pharmacology and Pharmaceutical SciencesLos AngelesUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-13081-1
  • Copyright Information American Association of Pharmaceutical Scientists 2015
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-319-13080-4
  • Online ISBN 978-3-319-13081-1
  • Series Print ISSN 2210-7371
  • Series Online ISSN 2210-738X
  • Buy this book on publisher's site
Industry Sectors
Pharma
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods